Status:
COMPLETED
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Pulmonary Disease, Chronic Obstructive
Asthma
Eligibility:
All Genders
40+ years
Phase:
PHASE4
Brief Summary
The objective of this trial is to compare the total and regional deposition of aerosol in the lungs and oropharynx of patients with COPD at 3 different inspiratory flow rates following inhalation of B...
Detailed Description
This is a single dose, randomised, active-controlled, six period, open-label cross-over trial in adult patients with COPD. Berodual (fenoterol hydrobromide 50 g + ipratropium bromide 20 g) will be de...
Eligibility Criteria
Inclusion
- COPD patients:
- FEV1 less or equal 65 % pre
- FEV1 less or equal 70 % of FVC
Exclusion
- Patients with any upper respiratory infection in the past 14 days prior to the Screening Visit (Visit 1)
- Patients with any unstable or life-threatening cardiac arrhythmia
Key Trial Info
Start Date :
September 26 2005
Trial Type :
INTERVENTIONAL
End Date :
December 7 2005
Estimated Enrollment :
19 Patients enrolled
Trial Details
Trial ID
NCT00153075
Start Date
September 26 2005
End Date
December 7 2005
Last Update
November 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Inamed Research GmbH & Co. KG
Gauting, Germany, 82131